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Abstract
Background:  There is growing evidence that inflammation plays an important role in
atherogenesis. Previous studies show that C-reactive protein (CRP), an inflammatory marker, is
associated with stroke outcomes and future vascular events. It is not clear whether this is due a
direct dose-response effect or rather an epiphenomenon. We studied the effect of CRP measured
within 24 hours after stroke onset on functional outcome, mortality and future vascular events.
Methods: We prospectively studied 498 patients with ischemic stroke who were admitted within
24 hours after the onset of symptoms. CRP and NIH stroke scale (NIHSS) were measured at the
time of admission. Short-term functional outcome was measured by modified Rankin scale (mRS)
and Barthel ADL index (BI) 7 days after admission. Patients were followed for up to 2.5 years for
long-term mortality and future vascular events data.
Results: The median CRP at admission was 3 mg/L. High CRP was associated with high NIHSS (p
= 0.01) and high long-term mortality (p < 0.0001). After adjusting for confounding variables, high
CRP remained to be associated with high NIHSS (p = 0.02) and high long-term mortality (p =
0.002). High CRP was associated with poor short-term functional outcomes (mRS > 3; BI < 95) (p
= 0.01; p = 0.03). However, the association was not significant after adjusting for confounding
variables including stroke severity (p = 0.98; p = 0.88). High CRP was not associated with future
vascular events (p = 0.98).
Conclusion: Admission CRP is associated with stroke severity and long-term mortality when
measured at least 24 hours after onset. There is a crude association between high CRP and short-
term functional outcome which is likely secondary to stroke severity. CRP is an independent
predictor of long-term mortality after ischemic stroke.
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Background
There is growing evidence that C-reactive protein (CRP), a
peripheral marker of inflammation, is also a marker of
generalized atherosclerosis [1]. This relationship between
inflammation and atherosclerosis make CRP a potential
marker for prognosis after vascular events and a potential
predictor of future vascular events.
Large population-based studies show that high CRP is a
risk factor for future cardiovascular events [2-4]. The
recent JUPITER trial shows that the use of rosuvastatin in
patients with high CRP has a significant impact both in
reducing the CRP level and in lowering future vascular
events [5]. This indicates the role of inflammation in
atherogenesis and suggests that CRP can be used as
marker of future events.
The role of CRP as a marker during and after ischemic
stroke is less extensively studied in comparison to coro-
nary artery disease. The Rotterdam study shows that
although high CRP is associated with the risk for future
stroke, it is not useful for individual stroke prediction [6].
On the other hand the Framingham study shows that high
CRP is associated with a greater risk for ischemic stroke or
TIA [7]. Studies in patients who already had a stroke
shows an association between high CRP and stroke pres-
entation, outcomes and future vascular events [8-14]. The
sample sizes in these studies, however, have been rela-
tively modest, and follow-up usually short (3–12
months). We conducted a collaborative review of 11 stud-
ies published between 1999 and 2004. There was substan-
tial variation in sample sizes (range 37–716), study design
(prospective, retrospective, controls included), subtype of
stroke included and main outcome measures [8-12,14-
19]. Moreover, the results from some studies were nega-
tive. In their pivotal review, Di Napoli et al concluded that
there is insufficient evidence to justify the routine use of
CRP for either primary or secondary risk stratification for
cerebrovascular disease alone [20]. In addition, only few
studies have analyzed the relationship between elevated
admission CRP levels and stroke severity or stroke etiol-
ogy. In short, there is need for more studies to clarify the
exact role of CRP in cerebrovascular disease.
The aim of this study was to help clarify the role of early
CRP in ischemic stroke by determining its association
with stroke severity, stroke etiology, functional outcome,
mortality and future vascular events, in a larger study than
most of the previous studies.
Methods
Data for this prospective study was obtained at Haukeland
University Hospital, Bergen, Norway, which serves a well-
defined population of 235,000. The study was done as a
part of a cohort study (The Bergen stroke study) in which
data was collected from all ischemic stroke patients admit-
ted to the department of neurology from February 2006 to
September 2008. Patients who were admitted more than
24 hours after the onset of symptoms were excluded.
Patients who were found with stroke or awoke with stroke
were included if it was known that the patient had been
normal <24 hours before blood sampling. Patients whose
clinical and radiological findings were not consistent with
stroke were excluded from the study.
At admission, plain CT scan of the head was done to rule
out haemorrhage. Blood samples for CRP were taken at
the time of admission, and analyzed by Tina-quant latex
method using Modular P (Roche Diagnostics). The NIH
stroke score (NIHSS) was assessed by a neurologist at the
time of admission. The NIHSS was categorized as 0–7, 8–
14 and >14. Eligible candidates were given intravenous
thrombolysis according to SITS-MOST protocol [21].
Risk factors were defined according to protocol. Hyperten-
sion (HTN) was defined as treatment with antihyperten-
sive drugs before stroke onset or introduction of
antihypertensive drugs before discharge. Diabetes melli-
tus (DM) was defined as treatment with glucose lowering
medications or diet prior to stroke onset, or a fasting
serum glucose >7.7 mmol/L during hospital stay. Smok-
ing was defined as the use of at least one cigarette per day
prior to stroke onset.
Based on the clinical presentation of stroke, patients were
classified according to the Oxford Community Stroke
Project (OCSP) classification [22]. The etiology of stroke
was classified according to TOAST criteria [23]. Clinical
details such as physiologic parameters, type of treatments
and radiographic findings were registered. Age was catego-
rized as <50, 50–59, 60–69 and ≥70 years. Outcome was
measured by modified Rankin Scale (mRS) and Barthel
ADL index (BI) 7 days after stroke onset. Poor outcome
was defined as mRS >2 or BI <95.
Survival data was obtained from the National Population
Registry of Norway, where all the permanent residents are
registered. Admissions for acute vascular events after the
index stroke admission were obtained from searches of
the electronic discharge diagnosis registry at the hospital
using ICD10 codes I20, I21, I22, I63, G45 (excluding
G454), I61, I74. These electronic events were then manu-
ally validated by two of the authors (JB, TI) and the time
to first future event of each type ascertained. Approxi-
mately half of the electronic discharge registry events were
false positives because of the re-use of the acute vascular
event diagnosis when the "sequelae of" should have been
used.BMC Neurology 2009, 9:18 http://www.biomedcentral.com/1471-2377/9/18
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Informed consent was obtained from all patients. The
study was approved by the local ethical committee.
Analysis
Due to the skewed distribution of CRP, we chose some-
what arbitrary cut points for CRP of 3 and 10 mg/dl, cor-
responding approximately to the median (50%) and
upper 20% distribution. The 3 mg/dl cut point corre-
sponds to the "high" CRP level in previous primary pre-
vention studies [24].
First, the prevalence of an elevated CRP was studied in var-
ious groups such as pre-stroke demographic factors, pre-
existing illness, risk factors for stroke, stroke severity and
time to hospital. A multivariate analysis was then per-
formed to identify independent predictors of an elevated
CRP.
To study the association of CRP with stroke severity, etiol-
ogy and outcomes we performed the following analysis.
The crude association of categories of CRP with stroke
severity (NIHSS and OCSP), etiology (TOAST), functional
outcome (mRS and BI), mortality and future vascular
events was computed. The Pearson χ2 test was used for
count table data, and the log rank test used for survival-
type tables. For the adjusted analysis, logistic regression
was used for most analyses. For dependent variables with
two outcome levels, ordinary logistic regression was. For
dependent variables with more than two outcome levels,
multivariate logistic regression was performed. For sur-
vival-type outcomes, Cox regression was used. For
dependent variables except stroke severity, we adjusted for
age, sex, diabetes, thrombolysis and stroke severity
(NIHSS). When stroke severity was the dependent varia-
ble, adjustment was done for age, sex, thrombolysis and
the presence of DM.
Results
During the inclusion period, 743 patients with ischemic
stroke were registered. Of these, 238 were excluded
because the interval between stroke onset and blood sam-
pling was >24 hours. Of the remaining, seven did not have
an admission CRP, leaving 498 patients for the present
analysis. The population characteristics with regards to
important pre-stroke risk factors, stroke presentation and
outcomes are shown in Table 1. The mean age (SD) of the
study population was 69.3 (14) years. Men, on average,
were 7.5 years younger than women. The distribution of
CRP (mg/L) values was highly skewed (median 3, 90%
percentile 18), with a somewhat higher geometric mean
value in women (3.7) than in men (3.1) (p = 0.08).
In table 2, we show the prevalence of an elevated CRP
according to various potential predictors, such as age and
sex, pre-existing illnesses, such as DM and coronary artery
disease, stroke severity and time to hospital. In univariate
analysis, only stroke severity (NIHSS, OCSP) and pre-
existing diabetes were significant. In a multivariate model
including one measure of stroke severity (NIHSS) and pre-
existing diabetes, an elevated CRP was independently pre-
dicted both by stroke severity and pre-existing diabetes (p
= 0.03; p = 0.04).
In Table 3 we show the association of CRP with stroke
severity, etiology, short-term outcome, mortality and
future vascular events. An elevated CRP was associated
with increased stroke severity (NIHSS, OCSP) (p = 0.01, p
= 0.006). Seventy nine percent of the low-CRP group had
a mild stroke (NIHSS<7), whereas only 60% of the high-
CRP group had a mild stroke. The most common stroke
subtype in the high CRP group was TACI (29%), whereas
in the low and medium CRP groups the most common
presentation was PACI (41% and 49%). The likely etiol-
ogy of stroke on the TOAST classification was statistically
significantly associated with CRP (p = 0.04). The high
CRP group had a higher frequency of stroke of cardioem-
bolic origin (38% in the high CRP group vs. 21% in the
low CRP group). CRP was associated with short-term
functional outcome on mRS (p = 0.04), with the high CRP
group having a 44% risk for a poor outcome vs. 26% for
the low CRP group. CRP was associated with short-term
functional outcome on BI (p = 0.03), with the high CRP
group having a 40% risk for poor outcome vs. 24% for the
low CRP group. CRP was not associated with future hos-
pital admissions for vascular events (p = 0.98).
Since CRP was associated with stroke severity and the pre-
existing DM, and the patient sample spanned a wide age
range, we wanted to see if the effect of CRP on outcomes
was independent of stroke severity, age, gender, effect of
intravenous thrombolysis and presence of DM. Both the
unadjusted (equivalent to table 3) and the adjusted multi-
nomial analysis are shown in Table 4. The unadjusted
analysis showed a significant association with stroke
severity, functional outcomes, mortality and etiology.
Stroke severity was associated with admission CRP even
after adjusting for age, sex, intravenous thrombolysis and
the presence of DM. After adjustment, CRP was predictive
of mortality but not for functional outcomes. Figure 1,
shows the event curves for survival and future vascular
events. The survival was poorer in the high CRP group not
only immediately after stroke, but also for our observa-
tion period of 2.5 years.
Discussion
Our study in ischemic stroke patients shows that a high
CRP at admission is associated with more severe stroke,
cardioembolic etiology, poor functional outcome and
high mortality. After adjusting for the effect of confound-
ing factors, high CRP remained to be associated with moreBMC Neurology 2009, 9:18 http://www.biomedcentral.com/1471-2377/9/18
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severe stroke and high mortality, but not with functional
outcome or etiology. CRP was not associated with future
vascular events.
The association between high CRP and a high stroke
severity remains unexplained. There is a distinct possibil-
ity that elevated CRP is a direct response to the extent of
cerebral tissue injury [25]. But as an inflammatory marker,
it is also possible that high CRP is associated with under-
lying processes that cause a more severe stroke. A small
number of papers with a relatively small number of
patients have studied the time course of CRP after stroke
onset [19,26-28]. Some of them have found an increase in
CRP after stroke. The level of increment had been either
very small – about one unit increase [19,27,28], or a very
large increase (10 units increase in 24 hours) [26]. These
discrepancies, too, remain unexplained. Whether high
CRP causes more severe stroke or vice versa needs to be
further studied in population-based larger cohort studies,
or in clinical studies with very early and closely spaced
repeated measurements.
The prognostic significance of early CRP after stroke has
significant clinical implications. Previous stroke studies
have shown an association between high CRP and poor
outcome [8,10,11,13,14,29]. Our study showed that the
long-term mortality was significantly associated with CRP
even after adjusting for age, sex and stroke severity. We
measured long-term mortality over a period of 2.5 years.
Since we did not have data on the causes of death, we can-
not be certain that the high mortality in patients with ele-
vated CRP is due to vascular events. If most of the death
were secondary to a vascular event, we would anticipate a
similar association between CRP and future vascular
events. However, this was not found in our study. The
results from a previous study also shows that CRP is asso-
ciated with the risk of death but not with vascular death or
future vascular events [12]. In clinical practice we may
Table 1: Sample size, distribution of risk factors, stroke presentation and outcomes in the 'Bergen stroke study' (n = 498) by sex
Men Women Total
Sample size 302 196 498
Risk factors
Age – mean (SD) 66.4 73.9 69.3
Total cholesterol – mean 5.04 5.91 5.39
Smoking – current smokers (%) 28 19 24
Hypertension (%) 46 57 51
Pre-existing diabetes mellitus (%) 13 13 13
Pre-existing cerebrovascular disease (%) 30 26 29
Pre-existing coronary artery disease (%) 25 16 21
Pre-existing cerebrovascular or coronary artery disease (%) 44 34 40
Stroke presentation
Time to blood test (%) <3 hours 38 35 37
3–6 hours 15 19 17
6–12 hours 12 11 12
12–24 hours 10 7 9
Awoke with Stroke (<24 hours) 16 14 15
Other (<24 hours) 7 11 8
OCSP classification (%) LACI 21 31 25
TACI 15 21 17
PACI 45 35 41
POCI 19 13 17
NIHSS (%) <7 74 68 72
7–13 13 16 14
14+ 11 12 11
Treated with i.v. thrombolysis (%) 20 17 19
NIHSS = National Institute of Health Stroke Score
OCSP = Oxford Community Stroke Project Classification
LACI = Lacunar infarct
TACI = Total Anterior Circulation Infarct
PACI = Partial Anterior Circulation Infarct
POCI = Posterior Circulation InfarctBMC Neurology 2009, 9:18 http://www.biomedcentral.com/1471-2377/9/18
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consider high CRP as a "red flag" marker of high mortal-
ity, but the therapeutic implications of this finding remain
uncertain.
The positive association between high CRP and cardioem-
bolic etiology is rather intricately related to stroke severity.
Stroke secondary to cardioembolism tends to have a
higher stroke severity. In our study the mean NIHSS of
stroke secondary to cardioembolism (7.7) was higher
than large-artery (4.2), small-vessel (3.1), and unknown
(5.1). This might explain why the association between
high CRP and cardioembolism was no more significant
after adjusting for confounding factors including stroke
severity. Apart from that, a large proportion of patients in
our study (42%) had unknown etiology which may add
further uncertainty.
Our study, in which CRP was measured within 24 hours
after stroke onset, showed a crude association between
high CRP and poor short-term functional outcome. How-
ever, when adjustment was done for confounding factors
including stroke severity, the association was no more sig-
nificant. We speculate that high CRP by itself is not dam-
aging per se. It is probably an epiphenomenon for poor
Table 2: Prevalence of an elevated CRP (>10 mg/L) in various patient subgroups in the 'Bergen stroke study' (n = 498)
Prevalence of elevated CRP (>10 mg/L)
Group % Univariate p-value Multivariate OR * Multivariate p-value**




Sex Male 14 0.28
Female 18
NIHSS <7 13 0.015 (ref) 0.03
7–13 25 2.15
14+ 21 1.89




Prior Cerebrovascular disease No 16 0.97
Yes 16
Pre-existing diabetes mellitus No 14 0.01 (ref) 0.04
Yes 27 1.96
Smoking habits Never smoker 19 0.29
Former smoker 14
Current smoker 12




Woke up with Stroke (<24 hours) 17
Other (<24 hours) 26
NIHSS = National Institute of health Stroke Score
OCSP = Oxford Community Stroke Project Classification
LACI = Lacunar infarct
TACI = Total Anterior Circulation Infarct
PACI = Partial Anterior Circulation Infarct
POCI = Posterior Circulation Infarct
* Odds ratio for the variables that were significant on multivariate stepwise logistic regression analysis.
** p-value for the variables that were significant on multivariate stepwise logistic regression analysis.BMC Neurology 2009, 9:18 http://www.biomedcentral.com/1471-2377/9/18
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outcome. A recent large population genetics study sug-
gests that CRP is partly genetically determined, and that a
high CRP level is not damaging per se [30].
Studies in patients free of vascular disease at baseline
show a positive association between high CRP and future
vascular events [31-33], We failed to show such an associ-
ation in stroke patients when CRP was measured within
24 hours after stroke onset. A few previous studies were
done in which CRP was measured early after stroke onset
(within 12 hours) [15,19,34]. Two of those studies failed
to show any association between CRP and future vascular
events [15,19], but one of them showed an association
between high CRP and future vascular events [34].
Chronic inflammation is considered to be a risk factor for
future vascular events [35]. Baseline CRP in the absence of
obvious causes like infection or inflammation may repre-
sent the chronic inflammatory status of a patient. CRP
level after the acute phase of stroke, however, is con-
founded by many factors including index stroke severity,
co-existing infections, stress and complications of stroke
such as deep vein thrombosis [14].
Table 3: Association of categories of admission CRP with two different measures of stroke severity (NIHSS, OCSP), stroke etiology 
(TOAST), stroke outcomes (mRS, BI, mortality) and future vascular events in the 'Bergen stroke study' (n = 498)
CRP in Categories*
<3 3–9.9 > = 10 p-value
NIHSS <7 79 73 60 0.01
7–13 10 16 24
14+ 11 11 16
Total 100 100 100
OCSP LACI 25 25 25 0.006
TACI 16 14 29
PACI 41 49 26
POCI 19 12 20
Total 100 100 100
TOAST Atherosclerosis 11 16 11 0.04
Cardioembolic 21 28 38
Small Vessel Disease 17 16 13
Other 3 2 5
Unknown 49 38 34
Total 100 100 100
BI >95 76 71 60 0.03
<95 24 29 40
Total 100 100 100
mRS 0–1 49 44 33 0.04
22 5 2 5 2 4
3–6 26 31 44
Total 100 100 100
Mortality 30-day 4 5 9 9.5E-08
6 months 4 11 20
12 months 5 13 31
2 years 8 15 44
Future Vascular Events 30-day 3 3 2 0.98
6 months 8 6 5
12 months 11 9 11
2 years 12 12 17
NIHSS = National Institute of Health Stroke Score
OCSP = Oxford Community Stroke Project Classification
TOAST = Trial of Org 10172 in Acute Stroke Treatment
mRS = Modified Rankin scale
BI = Barthel index
* Percentages within each CRP categories are shown columnsBMC Neurology 2009, 9:18 http://www.biomedcentral.com/1471-2377/9/18
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Some of limitations of our study must be acknowledged.
CRP was measured only at one time point (at admission).
Single CRP measurement can be influenced by many fac-
tors such as infections, stress, timing of measurement and
lab error. Serial measurements of CRP were not available
because this was not considered during the planning of
the epidemiological cohort that this study arises from.
Another limitation of the study was the un-availability of
a cause-specific survival data. Data on mortality from vas-
cular events only, would have been more ideal as this
would directly link the role of CRP in stroke outcome.
Another limitation of this study was the substantial heter-
ogeneity in stroke, and the subsequent necessity of a rela-
tively large sample size to detect effects. However,
compared to the previous studies, this is a relatively large
study. Given that the etiology of stroke is complex, the
sample size problem is expected.
Conclusion
A high admission CRP in ischemic stroke patients is
clearly associated with more severe stroke and high long-
term mortality. The clinical implications of these findings
are unclear at present. It remains to be seen whether CRP
is a marker of stroke severity, or is a response to stroke, or
a mixture of both.
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